CureVac (NASDAQ:CVAC) Shares Gap Down – Time to Sell?

CureVac N.V. (NASDAQ:CVAC)’s share price gapped down before the market opened on Friday . The stock had previously closed at $4.28, but opened at $4.15. CureVac shares last traded at $4.1550, with a volume of 546,855 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CureVac in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CureVac has an average rating of “Hold” and an average target price of $6.83.

CureVac Stock Performance

The stock has a 50-day simple moving average of $5.22 and a 200-day simple moving average of $5.29. The stock has a market cap of $927.64 million, a PE ratio of 5.74 and a beta of 1.77. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.70 and a quick ratio of 3.69.

CureVac (NASDAQ:CVAC) last issued its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%.The business had revenue of $63.53 million during the quarter, compared to analysts’ expectations of $21.40 million. Equities analysts predict that CureVac N.V. will post 0.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CureVac

A number of large investors have recently modified their holdings of the stock. Alpine Associates Management Inc. purchased a new position in CureVac in the 2nd quarter worth approximately $10,703,000. Qube Research & Technologies Ltd purchased a new position in shares of CureVac in the second quarter valued at $6,419,000. Water Island Capital LLC acquired a new stake in CureVac during the 2nd quarter valued at $5,197,000. AQR Arbitrage LLC increased its stake in CureVac by 2,145.7% during the 3rd quarter. AQR Arbitrage LLC now owns 991,688 shares of the company’s stock worth $5,345,000 after buying an additional 947,529 shares during the period. Finally, Magnetar Financial LLC acquired a new position in CureVac in the 3rd quarter worth $3,529,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.